Hemagen Diagnostics, Inc. (HMGN)

Market Cap	3.10K -97.5%
Revenue (ttm)	4.04M -21.4%
Net Income	-907.32K
EPS	-0.06
Shares Out	15.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	18,913
Open	0.0002
Previous Close	n/a
Day's Range	0.0002 - 0.0002
52-Week Range	0.0000 - 0.0402
Beta	1,067.16
RSI	48.07
Earnings Date	n/a

About Hemagen Diagnostics

Hemagen Diagnostics, Inc. provides human and veterinary diagnostic services worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its proprietary test kits are used to aid in the diagnosis of certain autoimmune and infectious diseases. It also provides human diagnostics, such as universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1985
• Employees: 15
• Stock Exchange: OTCMKTS
• Ticker Symbol: HMGN

Financial Performance

In fiscal year 2012, Hemagen Diagnostics's revenue was $4.04 million, a decrease of -21.38% compared to the previous year's $5.14 million. Losses were -$907,315, 3.05% more than in 2011.